Skip to content

VITROS recallZ-1267-2021 · Ortho-Clinical Diagnostics, Inc. · initiated Feb 12, 2021

Terminated

Is my device affected?

  1. Compare the model, catalog and lot or serial numbers on your device or its packaging with the code information below. A recall usually covers only specific models or lots.
  2. If yours is listed, follow the instructions from Ortho-Clinical Diagnostics, Inc. or your healthcare provider. The company's action is summarized under what the company is doing.
  3. Do not stop using a prescribed or implanted device on your own — talk to your healthcare provider first.

Where to find your model and lot numbers · What recall classes and statuses mean

Why it was recalled

VITROS Immunodiagnostic Products SARS-CoV-2 Antigen False Reactive Results Associated When Using Remel M4RT Viral Transport Media

FDA root cause category: Under Investigation by firm

What the company is doing

Ortho Clinical issued Urgent Product Correction Notification letter on 12 February 2021 (CL2021-064) stated reason , health risk and action to take: Ortho is collaborating with the manufacturer of Remel M4RT VTM to identify the root cause of the issue. " Ortho no longer recommends use of Remel M4RT VTM with the VITROS SARS-CoV-2 Antigen assay. " The VITROS SARS-CoV-2 Antigen Instructions for Use has been updated to remove Remel M4RT VTM from the Intended Use and to also add WHO formulation, Bartels FlexTrans and saline. The revised assay IFU is located on our website: https://www.orthoclinicaldiagnostics.com. Our website is the official source of information for all VITROS Products. Refer to the Revision History section included at the end of each IFU for a comprehensive list of changes. Technical changes in each IFU are marked by a change bar (|) to the left of the edited text. Discontinue use of Remel M4RT VTM and transition to an alternate media. " As your facility transitions to an alternate transport media, Ortho advises that your facility confirm the performance of each new lot of Remel M4RT VTM by doing the following: o Test each lot of Remel M4RT VTM with no specimen added, with and without the addition of extraction buffer. Suitable lots of Remel M4RT VTM will produce S/C values consistent with the values observed for the VITROS SARS-CoV-2 Antigen Control 1. o If possible, confirm the first 5 samples that produce reactive results on the VITROS SARS-CoV-2 Antigen assay using polymerase chain reaction (PCR) methodology, for each new lot of Remel M4RT VTM. " Post this notification by each system that processes the VITROS SARS-CoV-2 Antigen assay. " Complete the enclosed Confirmation of Receipt form no later than February 22, 2021. " Please forward this notification if the product was distributed outside of your facility.

Recall details

Recall number
Z-1267-2021
Status
Terminated
Initiated by the company
Feb 12, 2021
Recalling firm
Ortho-Clinical Diagnostics, Inc.
Quantity
12177 units
Product code
QKP
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Australia, Belgium, Canada L3R 4G5, Chile, Colombia, Denmark, France, Germany, India, Italy, Japan, Portugal, Russia, Singapore 609917, Spain, United Kingdom.

Product description

VITROS SARS-CoV-2 Antigen Reagent Pack - The VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent Pack when used in combination with the VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Calibrator is a chemiluminescent immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in nasopharyngeal (NP) specimens. For emergency authorization use only (EAU). Product Code: 6199941. OUS Product.

Code information (models, lots, serial numbers)

Any lot used with Remel M4RT VTM  UDI: 10758750033584

Devices named in this recall

1 device in the FDA device registry whose identifier appears in the recall's code information.

Product lines

Other products in the same recall event

The FDA groups related products into one recall event (event 87356).

Sources and updates

How recalls are matched to devices · Editorial policy · Report an error on this page